Bristol Myers Squibb (CELG-RI) EBITDA Margin Growth (3y) (2012 - 2026)
Bristol Myers Squibb (CELG-RI) EBITDA Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBITDA Margin Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
2,500.00 |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-91.00 |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
395.00 |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
1,527.00 |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-4,555.00 |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-53.00 |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
1,031.00 |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
-9,003.00 |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Bristol Myers Squibb |
244.56 Mn |
-10.21 Bn |
8.07 Bn |
546.00 |
| Date | Value |
|---|
| Mar 31, 2026 |
546.00 |
| Dec 31, 2025 |
-527.00 |
| Sep 30, 2025 |
268.00 |
| Jun 30, 2025 |
-432.00 |
| Mar 31, 2025 |
897.00 |
| Dec 31, 2024 |
-1,865.00 |
| Sep 30, 2024 |
-403.00 |
| Jun 30, 2024 |
407.00 |
| Mar 31, 2024 |
-12,007.00 |
| Dec 31, 2023 |
13,380.00 |
| Sep 30, 2023 |
2,083.00 |
| Jun 30, 2023 |
2,888.00 |
| Mar 31, 2023 |
5,597.00 |
| Dec 31, 2022 |
4,686.00 |
| Sep 30, 2022 |
2,300.00 |
| Jun 30, 2022 |
1,707.00 |
| Mar 31, 2022 |
869.00 |
| Dec 31, 2021 |
2,285.00 |
| Sep 30, 2021 |
499.00 |
| Jun 30, 2021 |
2,866.00 |
